GlassScriptPhysician profile
Stephanie A Shaw
NPI 1760687354
$1,571.58
in general payments reported to CMS, 2019-2025
23 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.42 · 2021: $25.65 · 2023: $321 · 2024: $488 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.24 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $125.57 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $107.01 | 2021-2024 | Freestyle Libre 3 |
| Insulet Corporation | $75.62 | 2019-2025 | Omnipod |
| Intuitive Surgical, INC. | $69.97 | 2023 | |
| Beta Bionics, INC. | $68.47 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $53.55 | 2025 | Yorvipath |
| Cequr Corporation | $53.41 | 2024 | Cequr Simplicity |
| Amgen INC. | $51.21 | 2025 | Evenity |
| Corcept Therapeutics | $38.58 | 2025 | Korlym |
| Ibsa Pharma INC. | $35.82 | 2023-2024 | Licart, Tirosint, Licart |
| Tandem Diabetes Care, INC. | $31.72 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $30.66 | 2025 | |
| Medtronic, INC. | $30.31 | 2025 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $29.05 | 2024 | Imcivree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $28.69 | 2025 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $25.35 | 2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $21.77 | 2025 | Recorlev |
| Currax Pharmaceuticals LLC | $17.31 | 2024 | Contrave |
| Sequel Med Tech, LLC | $17.08 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $15.77 | 2024 | |
| Medtronic Minimed, INC. | $11.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.